This document is a Japanese translation of the news release distributed by Viatris Inc. on June 29, 2026 (US local time) (Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy - Jun 29, 2026). English is the official language, and its content and interpretation shall take precedence. VR-205 Achieved Primary and Key Secondary Endpoints and Demonstrated Generally Good Tolerability Efficacy and Safety Profile of VR-205 in Japanese Patients Consistent with Known Profile from Global Clinical Trials Marketing Authorization Application Planned for 2026 Pittsburgh / Tokyo – June 29, 2026 – Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced positive top-line results from a Phase 3 study evaluating the efficacy and safety of VR-205 (budesonide targeted-release formulation) (Nefecon®) in adult Japanese patients with primary IgA nephropathy (IgAN) at risk of developing end-stage renal disease (ESRD). The Phase 3 study is a multi-center, interventional, open-label study evaluating the efficacy and safety of VR-205 administered at 16 mg in adult Japanese patients with primary IgA nephropathy (IgAN). Participants received treatment for 9 months, followed by a 3-month follow-up period. The study met its primary endpoint, demonstrating a 33.75 percent (95% CI: -45.27 to -19.80; p < 0.001) reduction in the geometric mean of the urine protein-to-creatinine ratio (UPCR) at 9 months compared to baseline. These results were statistically significant and clinically meaningful, consistent with the results from the global Phase 3 study of the product. A summary of the study results is provided below: In addition to statistically significant and clinically meaningful reductions in UPCR at 6 and 12 months, VR-205 showed a significant increase in estimated glomerular filtration rate (eGFR), a decrease in serum creatinine, and a reduction in the urine albumin-to-creatinine ratio (UACR) at 9 mo